Literature DB >> 24659324

Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5-20.0 ng/ml: a multicenter study.

Maping Huang1, Yurong Lin, Abai Xu, Matthew Uhlman, Xiangrong Deng, Xuanting Lin, Sifeng Wu, Pengfei Diao, Keji Xie, Ping Tang.   

Abstract

The prostate-specific antigen (PSA) "gray zone" in Chinese men is likely higher than the traditional value (2.5-10.0 ng/ml) since the incidence of prostate cancer in Chinese men is relative low. The utility of percent free PSA in predicting prostate cancer is based on Western populations and may introduce sizable bias when applied to a Chinese cohort. We assessed the efficacy of percent free PSA in predicting prostate cancer in Chinese men with a PSA of 2.5-10.0 and 10.1-20.0 ng/ml. A total of 558 men with a PSA of 2.5-20.0 ng/ml who had undergone prostatic biopsy to detect prostate cancer from two Chinese centers were included. The rates of prostate cancer in different percent free PSA ranges were evaluated. Receiver operating characteristic curve (ROC) was used to evaluate and compare the efficiency of PSA and percent free PSA in the diagnosis of prostate cancer. The areas under ROC (AUCs) for percent free PSA for predicting prostate cancer were not higher than those for PSA, although prostate cancer detection rates increased with decreased percent free PSA in men with a PSA of 2.5-10.0, 10.1-20.0, and 2.5-20.0 ng/ml. Similarly, for men aged <70 and ≥ 70 years and with prostate volume <40 and ≥ 40 ml, AUCs showed percent free PSA was not better than PSA in predicting prostate cancer. By analyzing multicenter data, we first found that percent free PSA does not improve detection of prostate cancer in Chinese men with a PSA of 2.5-10.0 or 10.1-20.0 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659324     DOI: 10.1007/s12032-014-0925-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.

Authors:  Nobumichi Tanaka; Kiyohide Fujimoto; Akihide Hirayama; Tatsuo Yoneda; Katsunori Yoshida; Yoshihiko Hirao
Journal:  Jpn J Clin Oncol       Date:  2010-03-18       Impact factor: 3.019

2.  Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men.

Authors:  Ping Tang; Wei Du; Keji Xie; Xiangrong Deng; Jingao Fu; Hui Chen; Wenjun Yang
Journal:  Urol Oncol       Date:  2011-08-24       Impact factor: 3.498

3.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

4.  Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.

Authors:  Ping Tang; Wei Du; Keji Xie; Jingao Fu; Hui Chen; Wenjun Yang; Judd W Moul
Journal:  Prostate       Date:  2011-05-02       Impact factor: 4.104

5.  The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.

Authors:  C Stephan; M Lein; K Jung; D Schnorr; S A Loening
Journal:  Cancer       Date:  1997-01-01       Impact factor: 6.860

6.  A meta-analysis of the performance characteristics of the free prostate-specific antigen test.

Authors:  Richard Lee; A Russell Localio; Katrina Armstrong; S Bruce Malkowicz; J Sanford Schwartz
Journal:  Urology       Date:  2006-04-05       Impact factor: 2.649

7.  The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.

Authors:  D K Ornstein; D S Smith; P A Humphrey; W J Catalona
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

Review 8.  Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.

Authors:  Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Christopher P Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

9.  The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.

Authors:  Juan Morote; Enrique Trilla; Salvador Esquena; Francesç Serrallach; José M Abascal; Aurelio Muñoz; Youssef Id M'Hammed; Inés M de Torres
Journal:  Eur Urol       Date:  2002-10       Impact factor: 20.096

10.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

Authors:  W J Catalona; D S Smith; R L Wolfert; T J Wang; H G Rittenhouse; T L Ratliff; R B Nadler
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

View more
  8 in total

1.  Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.

Authors:  Hai-Min Zhang; Yang Yan; Fang Wang; Wen-Yu Gu; Guang-Hui Hu; Jun-Hua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?

Authors:  Ning Xu; Yu-Peng Wu; Dong-Ning Chen; Zhi-Bin Ke; Hai Cai; Yong Wei; Qing-Shui Zheng; Jin-Bei Huang; Xiao-Dong Li; Xue-Yi Xue
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-05       Impact factor: 4.553

3.  Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.

Authors:  Rui Chen; Yiran Huang; Xiaobing Cai; Liping Xie; Dalin He; Liqun Zhou; Chuanliang Xu; Xu Gao; Shancheng Ren; Fubo Wang; Lulin Ma; Qiang Wei; Changjun Yin; Ye Tian; Zhongquan Sun; Qiang Fu; Qiang Ding; Junhua Zheng; Zhangqun Ye; Dingwei Ye; Danfeng Xu; Jianquan Hou; Kexin Xu; Jianlin Yuan; Xin Gao; Chunxiao Liu; Tiejun Pan; Yinghao Sun
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

4.  Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).

Authors:  Rui Chen; Li-Qun Zhou; Xiao-Bing Cai; Li-Ping Xie; Yi-Ran Huang; Da-Lin He; Xu Gao; Chuan-Liang Xu; Qiang Ding; Qiang Wei; Chang-Jun Yin; Shan-Cheng Ren; Fu-Bo Wang; Ye Tian; Zhong-Quan Sun; Qiang Fu; Lu-Lin Ma; Jun-Hua Zheng; Zhang-Qun Ye; Ding-Wei Ye; Dan-Feng Xu; Jian-Quan Hou; Ke-Xin Xu; Jian-Lin Yuan; Xin Gao; Chun-Xiao Liu; Tie-Jun Pan; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

5.  Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium.

Authors:  Rui Chen; Liping Xie; Xiaobing Cai; Yiran Huang; Liqun Zhou; Lulin Ma; Xu Gao; Chuanliang Xu; Shancheng Ren; Pengfei Shao; Danfeng Xu; Kexin Xu; Zhangqun Ye; Chunxiao Liu; Dingwei Ye; Li Lu; Qiang Fu; Jianquan Hou; Jianlin Yuan; Dalin He; Tie Zhou; Fubo Wang; Biming He; Yinghao Sun
Journal:  Asian J Urol       Date:  2015-04-16

6.  Endorectal power Doppler/grayscale ultrasound-guided biopsies vs. multiparametric MRI/ultrasound fusion-guided biopsies in males with high risk of prostate cancer: A prospective cohort study.

Authors:  Zhizhong He; Zhifan Yuan; Limei Liang; Xinx In Xie; Jianjun Yuan; Wenxu He; Junjun Chen; Yongpei Kuang
Journal:  Exp Ther Med       Date:  2019-10-31       Impact factor: 2.447

7.  Comparisons between magnetic resonance/ultrasound fusion-guided biopsy and standard biopsy in the diagnosis of prostate cancer: A prospective cohort study.

Authors:  Guangbin Zhu; Quan Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

8.  Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-DRE Urine Improves Diagnosis of Prostate Cancer in Chinese Population.

Authors:  Lie-Fu Ye; Sha He; Xiaopei Wu; Shengying Jiang; Ruo-Chen Zhang; Ze-Song Yang; Fa-Wen Chen; Dan-Ling Pan; Dong Li; Gang Li
Journal:  Prostate Cancer       Date:  2020-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.